Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Neoplasms, Plasma Cell 1Lymphoma 1Leukemia 1Hematologic Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 59fludarabine phosphate 52Peripheral Blood Stem Cell Transplantation 40Busulfan 39Tacrolimus 35Antilymphocyte Serum 34Mycophenolic Acid 33Radiotherapy 30Filgrastim 28Cyclosporine 25Melphalan 24Methotrexate 22Whole-Body Irradiation 21fludarabine 20Methylprednisolone 17Etoposide 16Cord Blood Stem Cell Transplantation 15sargramostim 9Rituximab 9Granulocyte Colony-Stimulating Factor 9Cytarabine 9Bortezomib 9Alemtuzumab 9Sirolimus 8Epoetin Alfa 7Psychiatric Rehabilitation 6Prednisone 6Flow Cytometry 6Carmustine 6Trimethoprim, Sulfamethoxazole Drug Combination 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Plasma Cell × Glycopeptides × Lymphoid × Clear all
NCT00195533 2009-11-16

Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients

Wyeth is now a wholly owned subsidiary of Pfizer

Completed
801 enrolled
Classical hematologyLymphoidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoma, Hematologic Neoplasms, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡